The 5-year disease-free survival rates of patients with or without PIK3CA amplifications were similar (44.1% vs. 46.7%, P=0.367), and those of the two groups with either early gastric cancer (79.6% vs. 88.6%, P=0.588) or advanced gastric cancer (37% vs. 40.2%, P=0.327) were also note significantly different. The gene discussed is PIK3CA; the disease is gastric cancer.